Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Short-term Investments: 2020-2025

Historic Short-term Investments for Tango Therapeutics (TNGX) over the last 4 years, with Sep 2025 value amounting to $94.5 million.

  • Tango Therapeutics' Short-term Investments fell 60.66% to $94.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year decrease of 60.66%. This contributed to the annual value of $188.4 million for FY2024, which is 30.36% down from last year.
  • Latest data reveals that Tango Therapeutics reported Short-term Investments of $94.5 million as of Q3 2025, which was down 33.24% from $141.5 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Short-term Investments peaked at $350.0 million during Q1 2022, and registered a low of $94.5 million during Q3 2025.
  • Over the past 3 years, Tango Therapeutics' median Short-term Investments value was $244.6 million (recorded in 2023), while the average stood at $224.4 million.
  • In the last 5 years, Tango Therapeutics' Short-term Investments spiked by 111.51% in 2021 and then plummeted by 60.66% in 2025.
  • Tango Therapeutics' Short-term Investments (Quarterly) stood at $342.5 million in 2021, then decreased by 10.61% to $306.2 million in 2022, then fell by 11.65% to $270.5 million in 2023, then plummeted by 30.36% to $188.4 million in 2024, then tumbled by 60.66% to $94.5 million in 2025.
  • Its Short-term Investments stands at $94.5 million for Q3 2025, versus $141.5 million for Q2 2025 and $158.3 million for Q1 2025.